Skip to main content
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1990 Sep;49(9):725–727. doi: 10.1136/ard.49.9.725

Antiproteinuric effect of captopril in a patient with lupus nephritis and intractable nephrotic syndrome.

Y Shapira 1, F Mor 1, A Friedler 1, A J Wysenbeek 1, A Weinberger 1
PMCID: PMC1004213  PMID: 2241292

Abstract

A 22 year old woman presented with lupus nephritis, hypertension, and intractable nephrotic syndrome. Albumin and furosemide given intravenously was ineffective. Captopril administered in a daily dose of 62.5 mg was associated with a reduction in proteinuria from 28 g/24 hours to 11.5 g/24 hours over 10 weeks, resulting in a weight reduction of 16 kg. This was achieved with relative preservation of renal function. Captopril should be considered in the treatment of intractable proteinuria in patients with lupus nephritis, or when cytotoxic drugs are refused, because of its efficacy and relative safety. Captopril should, however, be used as an adjunct and not as a substitute for standard treatment.

Full text

PDF
727

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Delfraissy J. F., Galanaud P., Balavoine J. F., Wallon C., Dormont J. Captopril and immune regulation. Kidney Int. 1984 Jun;25(6):925–929. doi: 10.1038/ki.1984.111. [DOI] [PubMed] [Google Scholar]
  2. Heeg J. E., de Jong P. E., van der Hem G. K., de Zeeuw D. Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int. 1987 Jul;32(1):78–83. doi: 10.1038/ki.1987.174. [DOI] [PubMed] [Google Scholar]
  3. Herlitz H., Edenö C., Mulec H., Westberg G., Aurell M. Captopril treatment of hypertension and renal failure in systemic lupus erythematosus. Nephron. 1984;38(4):253–256. doi: 10.1159/000183318. [DOI] [PubMed] [Google Scholar]
  4. Herlitz H., Tarkowski A., Svalander C., Volkmann R., Westberg G. Beneficial effect of captopril on systemic lupus erythematosus-like disease in MRL lpr/lpr mice. Int Arch Allergy Appl Immunol. 1988;85(3):272–277. doi: 10.1159/000234517. [DOI] [PubMed] [Google Scholar]
  5. Lagrue G., Robeva R., Laurent J. Antiproteinuric effect of captopril in primary glomerular disease. Nephron. 1987;46(1):99–100. doi: 10.1159/000184318. [DOI] [PubMed] [Google Scholar]
  6. Lewis E. J. Angiotensin-converting enzyme inhibitors: considerations regarding proteinuria. Am J Kidney Dis. 1987 Jul;10(1 Suppl 1):30–38. [PubMed] [Google Scholar]
  7. Taguma Y., Kitamoto Y., Futaki G., Ueda H., Monma H., Ishizaki M., Takahashi H., Sekino H., Sasaki Y. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med. 1985 Dec 26;313(26):1617–1620. doi: 10.1056/NEJM198512263132601. [DOI] [PubMed] [Google Scholar]
  8. Trachtman H., Gauthier B. Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease. J Pediatr. 1988 Feb;112(2):295–298. doi: 10.1016/s0022-3476(88)80073-8. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES